An Evaluation of Product Usage for Molecular Testing within Infectious Diseases

Table of Contents(Germany)

1.1 Project Objectives5

1.2 Definitions7

1.3 German HealthCareSystem and Reimbursement9

1.4 German Laboratory Landscape14

1.5 RespondentPopulation Germany15

2.1 Sexual TransmittedDiseases(STD)17

ChlamydiaTrachomatis19

Neisseria21

HIV22

HCV23

Group B Streptococcus24

HSV25

2.2 Mycobacteria25

MycobacteriaTuberculosis28

MycobacteriaAvium29

Mycobacteria?NA Purification31

2.3 AtypicalPneumoniae32

Bordetella33

Legionella33

Chlamydiasp.34

MycoplasmaPneumoniae35

2.4 Cytomegalovirus(CMV)36

CMV ?Qualitative Tests37

CMV ?Quantitative Tests37

2.5. ViralMeningitis38HSV 1 & 239

Enterovirus41

West NileVirus (WNV)41

Epstein BarrVirus (EBV)42

VZV43

2.6 RespiratoryViruses44

SARS45

Adenovirus46

Influenza A46

Influenza A&B47

RSV48

Parainfluenza48

2.7 HPV49

2.8 ChronicMeningitis50

2.9 BacterialMeningitis53

NeisseriaMeningitis54

HaemophilusInfluenza54

Pneumococcae55

Listeria55

Enterobacteria56

2.10 Tick Born Encephalitis56

2.11 AntibioticResistantBacteria59

2.12 Candida61

3. Equipment & Purchase63

3.1 CurrentInstallations& Financingof Laboratory Equipment63

Cobas Amplicor, Roche64

Light Cycler, Roche64

ABI PRISM, AppliedBiosystems64

RotorGene, CorbettResearch64

OtherCycler65

OtherDevices/Manufacturers66

3.2 Budget Resources67

3.3 WhoisInvolvedin PurchasingDecisions70

3.4 Howdo LaboratoriesPurchase72

3.5 CriteriaInfluencea PurchasingDecision74

3.6 WhatareLaboratoriesWillingto PayforNew Tests? 75

4. Market Sizesand Market Shares 76

4.1 Market VolumesforSelectedPathogens76

STD77

MycobacteriaTuberculosis78

AtypicalPneumonia78

CMV79

ViralMeningitis80

RespiratoryViruses81

HPV82

MRSA82

4.2 Market Shares83

5. Market Trends 85

5.1 Problems withMolecularDiagnostics85

5.2 ExpectedGrowth per Segment86

6.3 OtherGrowth Areas90

5.4 Drivers forMolecularDiagnostics91

5.5 RestraintsforMolecularDiagnostics92

6. PoliticalInfluences93

6.1 Changesof ReimbursementPolicy93

6.2 Influenceof the EU IVD Act94